ADMA Biologics, Inc. Annual report pursuant to Section 13 and 15(d)

13. SEGMENTS (Tables)

12 Months Ended

Dec. 31, 2019

Year Ended December 31, 2019
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	22,176,699		$	7,029,550		$	142,834		$	29,349,083

Cost of product revenue		33,306,858			6,197,380			—			39,504,238

Loss from operations		(29,360,522	)		(1,337,459	)		(10,726,346	)		(41,424,327	)

Interest and other expense, net		(1,091,993	)		13,521			(7,341,444	)		(8,419,916	)

Gain on transfer of plasma center assets		—			11,527,421			—			11,527,421

Loss on extinguishment of debt		—			—			(9,962,495	)		(9,962,495	)

Net (loss) income		(30,452,515	)		10,203,483			(28,030,285	)		(48,279,317	)

Capital expenditures		3,772,742			39,096			—			3,811,838
Depreciation and amortization expense		2,789,498			455,412			13,238			3,258,148
Total assets		100,461,050			3,967,860			22,661,815			127,090,725

Year Ended December 31, 2018
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	6,797,548		$	10,044,908		$	142,834		$	16,985,290

Cost of product revenue		35,485,273			6,709,362			—			42,194,635

Loss from operations		(45,633,715	)		(4,470,073	)		(10,185,156	)		(60,288,944	)

Interest and other expense, net		(1,077,624	)		(967	)		(4,375,910	)		(5,454,501	)

Net loss		(46,711,339	)		(4,471,040	)		(14,561,066	)		(65,743,445	)

Capital expenditures		1,580,684			514,916			—			2,095,600
Depreciation and amortization expense		2,608,776			814,768			22,854			3,446,398
Total assets		57,818,051			5,443,032			25,615,438			88,876,521